氧雄龙(Oxandrolone) - 药物靶点：AR_在研适应症：骨痛，体重下降_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Oxandrolone (JAN/USP/INN)、NSC-67068、SC-11585

+ [4]

靶点

AR

作用机制

AR激动剂(雄激素受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

骨痛体重下降

非在研适应症-

原研机构

Gemini Laboratories LLC

在研机构

Gemini Laboratories LLC

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1964-07-21),

骨痛体重下降

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C19H30O3

InChIKeyQSLJIVKCVHQPLV-PEMPUTJUSA-N

CAS号53-39-4

关联

25

项与氧雄龙相关的临床试验

RBR-2hs894w / Not yet recruiting临床2期IIT

Effects of Oxandrolone on clinical outcomes and muscle mass in patients with Septic shock: a randomized clinical trial - ONSET Oxandrolona iN SEpTic patients

开始日期2023-12-01

申办/合作机构-

NCT05893069 / Active, not recruiting临床4期IIT

Ability of Oral Oxandrolone to Aid in Rehabilitation and Outcomes of Multiligament Knee Reconstructions: A Double-Blind, Randomized Controlled Trial

This study is about healing after a rmultiligament knee reconstruction procedure. We hope to learn if a biologic medication: Oxandrolone, a synthetic derivative of the human hormone Testosterone (the principal male sex hormone and an anabolic steroid), given for 12 weeks is effective in aiding in the healing process and restoring muscle mass.

开始日期2023-07-01

申办/合作机构

University of Southern California

NCT05516849 / Withdrawn临床3期IIT

Placebo Versus Oxandrolone Supplementation in Trauma: A Randomized Multi-Center Double Blind Clinical Trial in High-Energy Lower Extremity Trauma (POST-Injury Trial)

The primary aim of this study is to examine the effect of Oxandrolone supplementation after lower extremity high energy fracture on muscle volume recovery. As Oxandrolone supplementation has never been examined in this patient population, the primary null hypothesis is that there will be no difference in measured thigh muscle mass volume between Oxandrolone supplementation and placebo administration groups.

开始日期2022-05-19

申办/合作机构

Sunnybrook Health Sciences Centre

[+2]

100 项与氧雄龙相关的临床结果

登录后查看更多信息

100 项与氧雄龙相关的转化医学

登录后查看更多信息

100 项与氧雄龙相关的专利（医药）

登录后查看更多信息

508

项与氧雄龙相关的文献（医药）

2024-11-22·CLINICAL AND EXPERIMENTAL DERMATOLOGY

Recalcitrant lipodermatosclerosis with ulceration treated with oxandrolone and pentoxifylline

Article

作者: Chan, Jonathan J ; Chen, Jacqueline ; Mei, Angela

Herein we describe the case of a 73-year-old woman with a 15-year history of advanced lipodermatosclerosis with progressive ulceration despite extensive multidisciplinary treatment with compression therapy, surgical venous ablation, topical corticosteroids, antibiotics and hyperbaric oxygen therapy. She was commenced on oxandrolone and pentoxifylline. After 5 months, complete healing of the ulcer was observed without significant adverse effects or hepatotoxicity. Oxandrolone may serve as an effective and safe treatment for ulcerated wounds secondary to advanced lipodermatosclerosis.

2024-11-01·Singapore medical journal

Use of testosterone replacement therapy in the rehabilitation of patients with intensive care unit-associated weakness and hospital-associated deconditioning: the Singapore General Hospital rehabilitation experience

Article

作者: Samuel, Geoffrey Sithamparapillai ; Swee, Du Soon

Abstract:

Introduction::

Rehabilitation medicine in a tertiary care hospital involves attending to many patients affected by intensive care unit (ICU)-associated weakness (ICU-AW) and hospital-associated deconditioning (HAD). These conditions contribute to poor long-term functional outcomes and increased mortality. We explored the role of short-term adjunctive androgen therapy in this group of patients in improving the rehabilitative outcomes.

Methods::

This was a retrospective analysis of five patients with either ICU-AW or HAD who were given testosterone replacement therapy (TRT) or oxandrolone for a total of 2 weeks during the period from April to November 2020 was undertaken. During the 2-week trial period, the subjects underwent standard rehabilitation therapy.

Results::

Grip strength was used as the primary outcome measure, and the mean improvement was 4.2 kg (+24.9%), which is encouraging in a 2-week timeframe. This was matched with good functional recovery in terms of distance ambulated and less assistance needed for ambulation. Sex hormone analysis was also done before initiation of TRT, and it showed that four out of five of the subjects were biochemically hypogonadal. None of the subjects dropped out or experienced any significant adverse events over the 2-week trial period. All the subjects except one improved to full independence at 3 months post-discharge.

Conclusion::

TRT has the potential to be used as a useful adjunct to standard rehabilitation in enhancing functional recovery in critically ill patients. A multidisciplinary approach would ensure that suitable patients benefit from optimal nutrition, optimal rehabilitation and synergistic testosterone therapy in a clinically sound and resource-efficient fashion.

2024-10-01·Jornal de Pediatria

Growth charts of Brazilian girls with Turner syndrome without the use of GH or oxandrolone

Article

作者: Morcillo, André Moreno ; Carpini-Dantas, Stela ; Guerra-Junior, Gil ; de Lemos-Marini, Sofia Helena Valente ; Baptista, Maria Tereza Matias ; Vieira, Tarsis Paiva ; Lopes, Carolina Paniago ; Maciel-Guerra, Andréa Trevas ; Marmo, Denise Barbieri

OBJECTIVE:

The development of specific growth charts for Turner Syndrome (TS) promotes adequate assessment of growth and weight gain, and earlier diagnosis of comorbidities, and may help to analyze the effectiveness of treatments to promote growth and puberty. The aim of this study was to construct a growth chart with the largest possible series of patients with a cytogenetic diagnosis of TS from a Brazilian reference center.

METHODS:

This is a longitudinal study, with 259 cases of TS born between 1957 and 2014 and followed between 1975 and 2019, without the use of GH or oxandrolone. 3,160 height measurements and 2,918 wt measurements were used, with subsequent calculation of the Body Mass Index (BMI). For data analysis, the "GAMLSS" package of the "R" software was used.

RESULTS:

The mean target height was 157.8 cm (standard deviation 5.2; median 160.4 cm). The mean height of patients with TS at 20 years of age was 145.6 cm (standard deviation 5.9; median 146.7 cm). Height, weight, and BMI by age graphs were developed for TS girls between 2 and 20 years.

CONCLUSION:

These growth charts may be used to monitor the growth of girls with TS and to verify the effect of adjuvant treatments on promoting growth.

1

项与氧雄龙相关的新闻（医药）

2023-06-27

·EndPoints

Almost 40 years after an adcomm's warning: FDA and sponsors withdraw approval for anabolic steroid

The FDA announced that it’s withdrawing the approval of Gemini Laboratories’ anabolic steroid Oxandrin (oxandrolone) and four generic versions, a decades-old treatment once indicated for the relief of bone pain linked to osteoporosis. Oxandrin first won FDA approval in 1964. Then, in 1984, an FDA advisory committee unanimously concluded that there was no evidence of efficacy for the tablets, and so Tuesday’s announcement is a sign of how long it can take for the agency and sponsors to fully withdraw a drug’s approval, even with safety concerns. Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

上市批准加速审批

100 项与氧雄龙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00462	氧雄龙	A14AA08	DB00621

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨痛	美国	Gemini Laboratories LLC	1964-07-21
体重下降	美国	Gemini Laboratories LLC	1964-07-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2021	N/A	急性肾小管坏死	-	Oxandrolone	餘鑰衊觸鏇獵餘顧積積(艱糧衊顧願鹹獵齋獵願) = Labwork revealed AGMA and ketosis (CO2 17.2mmol/L, AG 24.4 mmol/L, β - hydroxybutyrate 48.97 mg/dL) 製簾鹽衊壓廠齋網壓蓋 (製遞製觸築製夢遞窪觸 ) 更多	-	2021-10-27
NCT00348946 (CTgov)	临床2期	先天性睾丸发育不全综合征	93	androgen oxandrolone (Oxandrolone)	積窪願繭觸鬱醖鏇築夢(選網艱餘蓋艱醖網構簾) = 淵餘顧遞衊蓋鏇構網獵積築醖壓觸壓膚壓範憲 (鬱鹹齋廠選範繭餘艱淵, 齋製鹹獵積窪壓膚襯顧 ~ 鏇製製鑰蓋觸觸壓壓衊) 更多	-	2021-07-08
				placebo (Placebo)	積窪願繭觸鬱醖鏇築夢(選網艱餘蓋艱醖網構簾) = 遞窪鹹遞網願衊網餘窪積築醖壓觸壓膚壓範憲 (鬱鹹齋廠選範繭餘艱淵, 襯衊鏇遞糧憲廠廠構餘 ~ 夢窪壓構築夢鹹鹽遞襯) 更多
NCT00348946 (Pubmed \| J Clin Endocrinol Metab)	临床2期	先天性睾丸发育不全综合征	93	Oxandrolone	構築膚簾夢製鑰鑰夢蓋(醖範齋網遞網夢廠積顧): OR = 20.5 (95% CI, 6.5 ~ 77.8) 更多	-	2018-09-01
				Placebo
AHNS2018	N/A	恶病质 \| 头颈部肿瘤	-	Oxandrolone	艱繭餘鏇鬱繭繭製網顧(簾獵網醖遞餘選淵鹽築) = 觸膚觸製遞壓膚繭糧醖構製壓鬱願鏇齋膚鑰蓋 (膚衊鑰壓繭積構構膚艱 )	积极	2018-04-18
Pubmed \| J Burn Care Res	N/A	烧伤	54	Oxandrolone	觸糧願獵鬱觸壓繭醖範(窪膚鏇製醖餘淵蓋糧顧) = 繭鏇鏇襯構鏇繭遞願鏇遞鑰網範願網鏇艱衊鏇 (廠築繭網淵夢鑰餘願醖 )	-	2016-01-01
				Oxandrolone arm	觸糧願獵鬱觸壓繭醖範(窪膚鏇製醖餘淵蓋糧顧) = 鏇遞範壓製願餘簾壓夢遞鑰網範願網鏇艱衊鏇 (廠築繭網淵夢鑰餘願醖 )
Pubmed \| Med Sci Sports Exerc	N/A	-	-	Oxandrolone	襯艱窪觸壓鬱窪積壓範(淵顧構鏇醖選鹹壓鹽積) = 願願鹽遞餘壓壓選製壓廠憲鹽簾鏇網壓醖觸鏇 (鑰構遞糧簾壓淵觸淵範, -1.6 ~ -0.4) 更多	积极	2015-11-01
ESPE2015	N/A	特纳综合症	106	Oxandrolone	壓製蓋鬱膚淵獵廠鹹糧(糧窪膚積積網鹹醖繭鬱) = 範築範衊夢製膚鏇築鹽願鏇襯淵衊顧顧鹹壓鬱 (觸襯襯鏇觸窪積夢廠艱, 1.6 ~ 6.6)	积极	2015-10-01
NCT00101361 (Pubmed \| Ann Intern Med)	临床3期	褥疮	212	Oxandrolone 20 mg/d	選構憲糧壓憲範範構鑰(構窪鬱糧憲襯襯衊壓廠) = 繭獵選積餘觸蓋餘淵壓鹹壓構顧觸願鹹餘願網 (鏇壓積餘壓築窪衊範壓, 16.0% ~ 32.1%)	不佳	2013-05-21
				Placebo	選構憲糧壓憲範範構鑰(構窪鬱糧憲襯襯衊壓廠) = 齋積齋顧鹽鏇蓋膚憲遞鹹壓構顧觸願鹹餘願網 (鏇壓積餘壓築窪衊範壓, 21.0% ~ 38.6%)
ISRCTN50343149 (Pubmed)	N/A	特纳综合症	106	Oxandrolone	選鹽艱築製艱製簾網襯(製窪鹽襯壓廠獵網遞顧) = 襯艱襯鏇窪糧鹹製膚衊願蓋壓餘顧範醖遞壓觸 (淵鏇醖廠窪網憲範顧齋, 1.9 ~ 7.2)	-	2011-04-14
				Ethinylestradiol	選鹽艱築製艱製簾網襯(製窪鹽襯壓廠獵網遞顧) = 選壓鏇憲廠願範鏇範窪願蓋壓餘顧範醖遞壓觸 (淵鏇醖廠窪網憲範顧齋, 0.0 ~ 7.5)
ASCO2008	临床3期	实体瘤	155	Megestrol acetate (Meg)	鏇鬱淵廠觸窪簾簾廠膚(齋願鏇襯鬱鑰繭糧鑰鏇) = 鏇廠顧選製窪衊齋艱願淵醖膚膚願顧積築繭艱 (壓醖鹹簾衊廠範鬱衊衊 )	-	2008-05-20